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hat Is Left to Be Desired?*
tephan Windecker, MD, Lorenz Räber, MD
ern, Switzerland
rug-eluting stents (DES) were introduced into clinical
ractice after the pioneering work of Sousa et al. (1) in
ão Paulo, Brazil. The detailed first-in-man investiga-
ions of this renowned group supplemented by large-scale
linical trials established DES as a breakthrough tech-
ology due to their potent reduction of restenosis, the
rincipal shortcoming compared with coronary artery
ypass surgery and a nuisance in the quality of life of
ffected patients. Thus, first-generation DES with con-
rolled release of sirolimus or paclitaxel from durable
olymers has been consistently shown to reduce repeat
evascularization procedures by 40% to 70% compared
ith bare-metal stents (BMS) (2). The benefit, albeit
ttenuated, prevailed in studies without protocol-
andated angiographic follow-up, was particularly pro-
ounced in diabetic patients (3), and endured during
ong-term follow-up extending to 5 years.
See page 12
Although the efficacy of first-generation DES re-
ained undisputed, safety concerns soon emerged after
he widespread application of these devices in routine
linical practice with a wide range of on-label and
ff-label indications. Very late stent thrombosis, that is,
hrombotic occlusion of the device more than 1 year after
mplantation, was recognized as a distinct entity compli-
ating the use of first-generation DES with a continuous
isk up to 4 years (4). Human autopsy studies and recent
linical investigations of thrombosed DES specimens
mplied delayed healing, incomplete endothelialization,
nd vessel remodeling due to chronic inflammation as
otential mechanisms leading to this adverse event (5,6).
espite the somewhat increased risk of very late stent
hrombosis, comprehensive review of the available evi-
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the Department of Cardiology, Bern University Hospital, Bern, Switzerland.t
r. Windecker is a consultant for and receives lecture fees from Abbott, Biosensors,
iotronik, Boston Scientific, Medtronic, and Johnson & Johnson.ence showed similar rates of death and myocardial
nfarction among patients treated with DES and BMS
2). It has been suggested that the slightly increased risk
f very late stent thrombosis associated with DES is
ompensated by adverse events caused by the treatment of
he more frequent recurrences with BMS.
It is against this background that the results of the
ESIRE (Drug-Eluting Stents in the Real World)-Late
egistry (7) reported in this issue of JACC: Cardiovascular
nterventions must be critically appraised. During a me-
ian follow-up time of 5 years of 1,010 patients treated
ith first-generation DES (sirolimus- and paclitaxel-
luting stents) between 2002 and 2005, the cumulative
ate of cardiac death, target vessel revascularization, and
ajor adverse cardiac events amounted to 5.6%, 6.6%,
nd 15.4%, respectively. The rate of definite and probable
tent thrombosis was 1.7%, with more than one-half of
vents (0.9%) encountered beyond 1 year of stent implan-
ation. The investigators should be applauded for obtain-
ng complete follow-up information in more than 98% of
atients. Moreover, there was no protocol-mandated
ngiographic follow-up, thereby avoiding the oculoste-
otic reflex and the associated inflation of repeat revas-
ularization procedures.
Although these data are reassuring, event rates in the
ESIRE-Late study are low compared with long-term
ollow-up data derived from meta-analyses and large-
cale registries (Table 1) (2,8 –11) and require careful
crutiny. First, not all patients undergoing percutaneous
oronary intervention at this institution were treated with
ES. Instead, BMS were used in more than 50% of
atients in 2002 and still in 22% of patients in 2005. It
ould be of interest to compare event rates among DES
nd BMS because the selection of patients for a particular
tent type may have influenced the favorable results
selection bias). Along the same line, registry studies
ithout monitoring of all patients are susceptible to
etection bias because not all events may have been
aptured, particularly during longer-term follow-up.
Second, patients included at a single center in the
ESIRE-Late trial may not be representative of those
ncountered in routine clinical practice elsewhere. Al-
hough patient characteristics, including vessel size and
esion length, in the present study are comparable with
ublished all-comer patient populations, the mean num-
er of stents per patient (1.4) is rather low, suggesting
hat only 1 lesion was treated in the vast majority of
atients (4). This is of importance because the number of
reated lesions directly correlates with the risk of early
nd late ischemic and revascularization events as evi-
enced in the recent FAME (Fractional Flow Reserve
ersus Angiography for Multivessel Evaluation) trial
12). Moreover, the investigators paid particular atten-
ion to careful quantitative coronary analysis-guided stent
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20mplantation, which may have been instrumental in the
revention of adverse events related to poor stent implan-
ation technique.
Third, the proportion of patients with ST-segment
levation myocardial infarction (12%) at the time of the
ndex procedure as well as the incidence of thrombotic
esions (3%) is lower compared with that in previously
ublished DES registries (4). Acute myocardial infarc-
ion has been identified as an independent predictor of
ery late stent thrombosis, results in an increased inci-
ence of late acquired stent malapposition (13), and has
een associated with more extensive inflammation
nd a higher proportion of uncovered struts compared
ith stable lesions after DES implantation (14). The
ower proportion of patients with acute myocardial in-
arction in the DESIRE-Late trial therefore may have
ontributed to the low incidence of very late stent
hrombosis.
Fourth, the low overall (1.7%) and very late (0.13% per
ear) rate of definite and probable stent thrombosis is
eminiscent of recent results obtained in the Japanese
ypher registry, with a cumulative incidence of only 0.9%
Table 1. Clinical Long-Term Outcomes With First-Generation DES
Author (Ref. #) n
Follow-Up Time
(yrs) DES Type
Stettler et al. (2) 6,771 4 SES
Stettler et al. (2) 6,331 4 PES
Stone et al. (8) 1,748 4 SES
Stone et al. (8) 3,513 4 PES
Daemen et al. (4) 8,146 3 DES
Kimura et al. (9) 10,778 2 SES
Tu et al. (10) 3,751 2 DES
Mauri et al. (11) 5,549 2 DES
DES drug-eluting stent(s); MImyocardial infarction; NA not applicable; PES paclitaxel-elut
Table 2. Clinical Outcomes of Trials With Newer-Generation DES
Trial
(Ref. #) n Indication
Clopidogrel
Therapy
(Months)
Follow-Up
Time DES Type
Car
De
(
SPIRIT II
(15)
300 Selected
patients
6 3 yrs EES vs. PES 0.5 v
p 
SPIRIT III
(16)
1,002 Selected
patients
6 3 yrs EES vs. PES 1.6 v
p 
SPIRIT IV
(17)
3,690 Selected
patients
12 12 months EES vs. PES 0.4 v
p
ENDEAVOR
II (18)
1,197 Selected
patients
3 5 yrs ZES vs. BMS 3.1 v
p 
ENDEAVOR
III (19)
436 Selected
patients
3 4 yrs ZES vs. SES 0.3 v
p 
ENDEAVOR
IV (20)
1,548 Selected
patients
6 3 yrs ZES vs. SES 1.6 v
p EES everolimus-eluting stent(s); MACEmajor adverse cardiovascular events; ZES zotarolimus-elutin9). Of note, these results were observed despite a
elatively short duration of dual-antiplatelet therapy of 3
o 6 months. Ethnic differences may come into play as
hey relate to the propensity for the development of
ypersensitivity reactions to DES or nonresponsiveness
o the thienopyridine clopidogrel and render the results
ifficult to apply to other patient populations.
How do we apply the results of the DESIRE-Late study
o clinical practice? It is certainly reassuring for patients as
ell as responsible physicians that first-generation DES are
ssociated with an excellent long-term clinical outcome in
ppropriately selected patients, even in the presence of a
hort-duration regimen of dual-antiplatelet therapy. Not-
ithstanding, the results have been obtained with the first
eneration of sirolimus- and paclitaxel-eluting stents, which
ave been superseded by the advent of newer-generation
ES. Excellent short- and long-term clinical outcome have
een reported with newer-generation DES, as summarized
n Table 2 (15–20). Although it is still premature to
efinitively conclude, available data suggest that newer-
eneration DES may put to rest previous concerns of very
ate stent thrombosis.
ath
%)
Cardiac Death
(%)
MI
(%)
TLR
(%)
Per Protocol
Stent Thrombosis
7.3 4.2 4.4 6.9 1.4
7.4 4.2 5.4 9.8 2.3
6.7 3.5 6.4 7.8 1.2
6.1 2.4 7.0 10.1 1.3
0.3 NA 4.1 11.7 2.9
7.2 3.7 1.5 10.2 0.8
4.3 NA 5.7 7.4 NA
9.8 NA 8.3 11.0 NA
t(s); SES sirolimus-eluting stent(s); TLR target lesion revascularization.
MI
(%)
TLR
(%)
MACE
(%)
Definition of
MACE
Per Protocol
Stent Thrombosis
3.6 vs. 7.2
p  NS
4.6 vs. 10.1
p  NS
7.2 vs. 15.9
p  0.05
Cardiac death,
MI, TLR
2.1 vs. 4.4
p NS
3.8 vs. 6.6
p  0.07
5.7 vs. 9.2
p  NS
9.7 vs. 16.4
p  0.004
Cardiac death,
MI, TLR
1.0 vs. 1.7
p NS
1.9 vs. 3.1
p 0.02
2.5 vs. 4.6
p 0.001
4.2 vs. 6.9
p 0009
Cardiac death,
MI, TLR
0.2 vs. 0.9
p 0.004
3.8 vs. 4.8
p  NS
7.5 vs. 16.3
p  0.001
15.4 vs. 24.6
p  0.001
Death, MI, TLR 0.5 vs. 1.4
p NS
1.0 vs. 4.5
p  0.05
7.8 vs. 6.4
p  NS
12.7 vs. 19.1
p  NS
Death, MI, TLR 0.0 vs. 0.0
p NS
2.2 vs. 4.9
p  0.007
6.5 vs. 6.0
p  NS
11.4 vs. 13.8
p  NS
Death, MI, TLR 1.0 vs. 1.0
p NSDe
(
1diac
ath
%)
s. 4.3
NS
s. 2.0
NS
s. 0.4
NS
s. 3.6
NS
s. 1.8
NS
s. 2.3
NSg stent(s); other abbreviations in Table 1.
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